TABLE 3.
Immune responses of vaccinated macaques correlated with reduced viral burdensa
| Cellular or humoral response by viral burden group |
P value at:
|
|||
|---|---|---|---|---|
| Peak prechallenge | Time of challenge | Wk 2 postchallengeb | Wk 4 postchallengeb | |
| Cellular response | ||||
| Envelope | ||||
| Intermediate versus high | 0.057 | 0.057 | ||
| Low plus intermediate versus high | 0.024 | |||
| Low versus intermediate versus high | 0.028 | 0.014 | ||
| Gag | ||||
| Low versus intermediate versus high | 0.0039 | 0.0013 | ||
| Paired Gag and envelope | ||||
| Low plus intermediate versus high | 0.051 | |||
| Humoral response | ||||
| Binding Antibody to gp120: Nasal IgG | ||||
| Low versus high | 0.029 | |||
| Low plus intermediate versus high | 0.028 | |||
| Paired Nasal IgG plus IgA | ||||
| Low versus high | 0.029 | |||
| Low plus intermediate versus high | 0.032 | |||
| Paired vaginal plus nasal IgG | ||||
| Low versus high | 0.029 | |||
| Low plus intermediate versus high | 0.042 | |||
| Paired serum, nasal, and vaginal IgG | ||||
| Low versus high | 0.029 | |||
| Low plus intermediate versus high | 0.057 | |||
| Neutralizing antibody | ||||
| Low versus high | 0.057 | |||
P values <0.05 are considered statistically significant. We also report comparative outcomes approaching statistical significance.
Postchallenge comparisons include both immunized and control non-Mamu-A∗01 macaques.